TAK-079 is a fully human, non-agonistic, IgG1 cell-depleting monoclonal antibody that binds human CD38 with high affinity.
| SparkCures ID | 310 |
|---|---|
| Developed By | Takeda Oncology |
| Generic Name | TAK-079 |
| Treatment Classifications | |
| Treatment Targets |
There are no resources, links or videos to display for this treatment.
SparkCures is working closely with Takeda Oncology to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners